License and Collaboration Agreement Between Biogen International GmbH and Catalyst Biosciences, Inc.License and Collaboration Agreement • February 20th, 2020 • Catalyst Biosciences, Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is entered into as of December 18, 2019 (the “Effective Date”) by and between Biogen International GmbH, a company organized and existing under the laws of Switzerland and having a principal place of business at Neuhofstrasse 30, Baar, 6340, Switzerland (“Biogen”) and Catalyst Biosciences, Inc., a Delaware corporation having a principal place of business at 611 Gateway Blvd., Suite 710, South San Francisco, CA 94080 (“Catalyst”). Biogen and Catalyst are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Mosaic Biosciences, Inc. Amended and Restated Collaboration AgreementCollaboration Agreement • February 20th, 2020 • Catalyst Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Collaboration Agreement (“Agreement”) is entered into as of this 18th day of December 2019 (“Amendment No. 2 Effective Date”), by and between Mosaic Biosciences, Inc., a Delaware corporation, with its principal place of business located at 3415 Colorado Ave., Boulder, CO 80303 (“Mosaic”), and Catalyst Biosciences, Inc., a Delaware corporation, with its principal place of business located at 611 Gateway Blvd. Suite 710, South San Francisco, CA 94080 USA (“Catalyst”). Mosaic and Catalyst may be referred to individually herein as a “Party” and collectively as the “Parties”.
